Ichnos Sciences is the latest addition to Biopôle’s growing corporate network. This collaboration combines Biopôle’s diverse and ambitious life sciences community and ecosystem with Ichnos Sciences’ innovative approach to developing multispecific antibodies in oncology.
Launched in 2019, Ichnos Sciences aims to treat disease holistically, seeking to provide curative therapies that extend human life and improve quality of life. The company has headquarters in New York City with additional teams based at La Chaux-de-Fonds and, of course, Biopôle, site of SIP West EPFL for its R&D activities.
Ichnos’ research being conducted at Biopôle has the potential to contribute to the company’s vision of driving medicine forwards. The collaboration will enable important connections between Ichnos Sciences and other members of the Biopôle community.
Eugene Zhukovsky, Chief Scientific Officer at Ichnos Sciences, says: ‘Ichnos Sciences welcomes collaboration with partners that have bold ideas and capabilities that complement and stretch our potential to shift progress, advance science and deliver transformative medicines. The Biopôle community offers these kinds of opportunities.’
Biopôle’s CEO, Nasri Nahas, commented: ‘We are thrilled to welcome Ichnos Sciences, already a member of our community, to our corporate partnership programme. We are confident that there will be mutually beneficial opportunities for them and for Biopôle’s community members.’
Corporate partners benefit from the opportunity to participate in Biopôle’s innovation programmes StartLab and the Digital Health Hub, access infrastructure, incubate new ideas and projects of interest and host projects directly on campus.